Cardinal Health Q3 2026 Earnings Snapshot

Cardinal Health (CAH) has put up another big quarter, with Q2 2026 revenue at US$65.6b, basic EPS of US$1.98 and net income of US$467m setting the tone for its latest earnings update. Over the past six reported quarters, revenue has moved from US$52.3b in Q1 2025 to US$65.6b in Q2 2026, while basic EPS has ranged from US$1.00 in Q4 2025 to US$2.11 in Q3 2025. This gives you a clear line of sight on how the top line and EPS have tracked together. With trailing 12 month earnings up 26.7% and net profit margin edging up to 0.7%, the story this quarter is about how a low margin model is still converting heavy revenue into growing profits.

See our full analysis for Cardinal Health.

With the headline numbers on the table, the next step is to see how these results line up with the most common narratives around Cardinal Health and where the data either supports or pushes back on those stories.

8% revenue growth with thin 0.7% margin

• Over the last twelve months, Cardinal Health generated US$244.7b in revenue with net income of US$1.7b, which works out to 8% revenue growth and a 0.7% net margin compared with 0.6% a year earlier.
• Analysts' consensus view sees Cardinal leaning on volume growth and efficiency, and the margin data partly lines up with that:
  • The consensus narrative expects automation and portfolio optimization to support margin improvement. The move from a 0.6% to 0.7% net margin over the last year is consistent with that direction, even if the level remains low for a large distributor.
  • At the same time, revenue growth of 8% over the trailing year sits below the US market forecast of 11% per year cited in the data. This is a reminder that volume growth alone may not fully deliver the margin expansion that bulls focus on.

Consensus holders who want to see how these growth and margin trends tie into the broader story can tap into investor narratives and valuation work in one place with the See what the community is saying about Cardinal Health

Earnings up 26.7% with higher P/E

• Trailing twelve month earnings rose 26.7% to US$1.7b, and at a share price of US$192.88 the stock trades on a trailing P/E of 27.3x, above both the peer average of 24.2x and the US Healthcare industry average of 24.6x.
• What stands out for the bullish narrative is that the earnings trend broadly lines up with the growth story, but the P/E already sits at a premium:
  • Consensus expects earnings to grow about 9.6% per year, and the recent 26.7% earnings growth gives bulls some support that the business is currently producing earnings expansion faster than that medium term forecast.
  • However, with the P/E at 27.3x versus an analyst target price of US$246.93, investors who agree with the bullish view still have to decide whether that premium multiple is reasonable given the 9.6% earnings growth expectation.

Bulls who want to see how optimistic investors connect this earnings growth and premium multiple to a longer term upside case can unpack the full argument in the 🐂 Cardinal Health Bull Case

DCF fair value and debt risk in tension

• The supplied model shows a DCF fair value of US$540.74 versus the current share price of US$192.88. The stock is described as trading 64.3% below that DCF fair value while analysts' target of US$246.93 sits above the market price, all against a backdrop of high debt and recent insider selling.
• Bears focus on that balance sheet and insider activity, and the data gives them clear talking points even alongside the large modeled upside:
  • Critics highlight the high level of debt as a key risk, which directly matters when net margin is only 0.7% because there is limited room for error if financing costs or reimbursement terms move against the company.
  • Skeptics also point to significant insider selling over the past three months as a signal to treat the large gap between the US$192.88 share price and the US$540.74 DCF fair value with caution, rather than assuming that the modeled upside will necessarily be realized.

Investors who want to see how cautious analysts frame these debt and insider selling concerns against the large modeled upside can walk through the full bear case in the 🐻 Cardinal Health Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cardinal Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of optimism and concern running through this update, it makes sense to move quickly, check the numbers yourself, and weigh both sides. To see how the key positives sit alongside the main worries, take a closer look at the 4 key rewards and 2 important warning signs.

See What Else Is Out There

Cardinal Health pairs a thin 0.7% net margin with high debt and insider selling, which can leave little room for error if conditions tighten.

If that mix feels uncomfortable, you can quickly compare it with companies screened for stronger finances and lower perceived risk by checking out the 76 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.